Premium
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
Author(s) -
Estcourt L. J.
Publication year - 2019
Publication title -
transfusion medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 59
eISSN - 1365-3148
pISSN - 0958-7578
DOI - 10.1111/tme.12615
Subject(s) - thrombotic thrombocytopenic purpura , medicine , platelet , purpura (gastropod) , gastroenterology , biology , ecology
SUMMARY Clinical question In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage? Evidence from trial In adults with acquired TTP, caplacizumab decreased the time to normalisation of the platelet count and decreased the risk of TTP‐related death and recurrence of TTP.